Zacks Research Has Bullish Estimate for WST Q3 Earnings

West Pharmaceutical Services, Inc. (NYSE:WST) – Stock analysts at Zacks Research boosted their Q3 2026 EPS estimates for shares of West Pharmaceutical Services in a note issued to investors on Thursday, November 13th. Zacks Research analyst Team now expects that the medical instruments supplier will earn $1.95 per share for the quarter, up from their prior forecast of $1.82. Zacks Research currently has a “Hold” rating on the stock. The consensus estimate for West Pharmaceutical Services’ current full-year earnings is $6.62 per share. Zacks Research also issued estimates for West Pharmaceutical Services’ Q4 2026 earnings at $1.91 EPS and Q2 2027 earnings at $2.22 EPS.

Several other research firms have also recently weighed in on WST. Barclays raised their target price on shares of West Pharmaceutical Services from $275.00 to $325.00 and gave the company an “equal weight” rating in a research note on Monday, October 27th. Rothschild Redb upgraded shares of West Pharmaceutical Services to a “strong-buy” rating in a research note on Monday, September 15th. Weiss Ratings reissued a “hold (c)” rating on shares of West Pharmaceutical Services in a research report on Tuesday, October 14th. Redburn Partners set a $311.00 price objective on shares of West Pharmaceutical Services in a research note on Monday, September 15th. Finally, Rothschild & Co Redburn assumed coverage on shares of West Pharmaceutical Services in a research note on Monday, September 15th. They issued a “buy” rating and a $311.00 target price for the company. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $349.20.

West Pharmaceutical Services Stock Up 0.4%

NYSE:WST opened at $262.30 on Monday. West Pharmaceutical Services has a twelve month low of $187.43 and a twelve month high of $348.90. The firm has a market capitalization of $18.87 billion, a price-to-earnings ratio of 38.86, a price-to-earnings-growth ratio of 4.09 and a beta of 1.08. The company has a quick ratio of 2.18, a current ratio of 2.87 and a debt-to-equity ratio of 0.07. The stock’s 50 day moving average price is $268.90 and its two-hundred day moving average price is $242.34.

West Pharmaceutical Services (NYSE:WST) last released its earnings results on Thursday, October 23rd. The medical instruments supplier reported $1.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.67 by $0.29. West Pharmaceutical Services had a return on equity of 18.16% and a net margin of 16.29%.The business had revenue of $804.60 million for the quarter, compared to analyst estimates of $788.42 million. During the same quarter in the prior year, the company posted $1.85 earnings per share. West Pharmaceutical Services’s revenue was up 7.7% on a year-over-year basis. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its holdings in shares of West Pharmaceutical Services by 4.2% during the third quarter. Vanguard Group Inc. now owns 9,704,948 shares of the medical instruments supplier’s stock worth $2,545,899,000 after acquiring an additional 388,144 shares during the period. State Street Corp boosted its stake in West Pharmaceutical Services by 2.1% in the 2nd quarter. State Street Corp now owns 3,271,866 shares of the medical instruments supplier’s stock valued at $715,884,000 after purchasing an additional 68,330 shares during the period. Artisan Partners Limited Partnership grew its holdings in West Pharmaceutical Services by 22.2% in the 3rd quarter. Artisan Partners Limited Partnership now owns 2,770,920 shares of the medical instruments supplier’s stock valued at $726,895,000 after buying an additional 503,601 shares in the last quarter. Durable Capital Partners LP grew its holdings in West Pharmaceutical Services by 146.8% in the 1st quarter. Durable Capital Partners LP now owns 1,573,119 shares of the medical instruments supplier’s stock valued at $352,190,000 after buying an additional 935,721 shares in the last quarter. Finally, APG Asset Management N.V. increased its position in West Pharmaceutical Services by 8.7% during the 1st quarter. APG Asset Management N.V. now owns 1,562,139 shares of the medical instruments supplier’s stock worth $323,766,000 after buying an additional 124,737 shares during the period. 93.90% of the stock is owned by institutional investors.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.